Abstract
The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.
Keywords: Anti-VEGF, diabetic macular edema, diabetes, neovascularization, rethinopathy, vision loss prevention.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Metabolism
Related Books
Frontiers in Clinical Drug Research-Dementia
COVID-19: Causes, Transmission, Diagnosis, and Treatment
Skeletal Muscle Health in Metabolic Diseases
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Common Lip Diseases: A Clinical Guide
Interventional Pain Surgery
Endoscopy and Fetoscopy Techniques for the Brain and Neuroaxis
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Frontiers in Stem Cell and Regenerative Medicine Research
38